These results suggest that SPARC mediates active targeting of HSA in U87MG gliomas and, therefore, HSA-mediated anti-cancer drug delivery for highly malignant gliomas and other SPARC-expressing cancers has great potential in the clinic. Here, ALB is linked to cancer.